Investor Info

StromaGenesis is a pre-revenue oncology diagnostics company with over $13 million already invested and is now seeking an additional $15 million in equity financing to commercialize first-in-class molecular diagnostic tools aimed at significantly improving cancer treatment decisions and patient outcomes.

Built on more than 18 years of rigorous academic development, StromaGenesis’ platform comprises:

A proprietary algorithm delivering superior precision in prostate cancer prognosis
A tissue-based immunoassay that predicts therapeutic response across multiple high-incidence solid tumors, including breast, colon, prostate, and glioblastoma
A suite of tissue- and blood-based immunoassays designed as companion diagnostics to guide treatment selection across numerous solid tumor types